NeOnc Technologies (NTHI) announced the award of two competitive NIH STTR grants totaling $2.5 million. These non-dilutive funds will further advance development of the company’s proprietary therapeutic compound NEO212, which is currently completing its Phase 1 clinical trial. $400,000 Phase 1 STTR Grant: Supports preclinical feasibility studies of NEO212 in acute myelogenous leukemia. Dr. Thomas Chen serves as NeOnc’s Principal Investigator, with Dr. Axel H. Schonthal leading the academic research effort at USC’s Glioma Research Group. $2.1 Million Phase 2 STTR Grant: Focused on expanding NEO212’s clinical development into newly diagnosed gliomas, reinforcing the therapeutic’s broad oncologic potential. Dr. Chen is the PI for NeOnc, with Dr. Radu Minea leading the USC component.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc Technologies Acquires AI and Quantum IP Portfolio
- NeOnc Technologies Signs Definitive Agreement for Acquisition
- NeOnc to acquire AI, 3D, quantum modeling IP portfolio from Puri
- NeOnc signs definitive agreement for $50M strategic partnership with Quazar
- NeOnc Technologies Signs Sub-License Agreement with NuroCure